Earlier research has also shown that CDCA5 might influence cell malignant behavior in prostate cancer, bladder cancer, and hepatocellular carcinoma through modulating PI3K/AKT/mTOR signaling [7, 9, 10]. This evidence concerns the gene CDCA5 and prostate cancer.